Caterina Vivaldi

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC

Marzia Del Re, Riccardo Marconcini, G. Pasquini et al. · British Journal of Cancer · 2018 · 242 citations · Full text

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2022 · 123 citations · Full text

Oncology, Hepatology, Medicine +8

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

Margherita Rimini, Lorenzo Fornaro, Sara Lonardi et al. · Liver International · 2023 · 110 citations · Full text

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)

Lorenzo Fornaro, Sara Lonardi, Gianluca Masi et al. · Annals of Oncology · 2013 · 98 citations · Full text

Phase Ii Trial, Gastrointestinal Oncology, Medicine +7

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D’Alessio et al. · European Journal of Cancer · 2022 · 98 citations · Full text

Drug Safety, Oncology, Medicine +9